While showing good efficacy in treatment naive patients, the SPRINT study -- presented today, at EASL 2009 in Copenhagen -- which is a trial of Schering's Boceprevir candidate also presented anemia in half of all patients, per a Reuters report:
. . . .But half the patients taking the boceprevir experimental medicine developed anemia -- a potential commercial disadvantage to a similar pill called telaprevir that Vertex Pharmaecutical Inc (VRTX.O) is developing. . . .
In my estimation, this makes Vertex's Teleprevir the clear winner -- in this horse race. Teleprevir is curing half of all previously-failed-therapy Hep C patients -- and Schering's doesn't show any real promise, there.